NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

CBS promotes John McEnroe as prostate expert without disclosing pharma funding

Posted By


No surprise. Just another terrible example of the one-sided – potentially harmful – information often disseminated on the network TV morning programs. See the latest review of the CBS Early Show on

It wraps up a very good week for former tennis star John McEnroe. But not so good for men who may have seen him on TV.

* A prime time appearance on CNN’s Larry King Live promoting prostate cancer screening
* A CBS Early Show appearance promoting prostate cancer screening

And he was getting paid all the time by a drug company – something clearly noted on the website that McEnroe promoted – but something CBS never disclosed on the air.

GlaxoSmithKline funded and helped develop this campaign, including providing compensation to Mr. McEnroe.

CBS merely turned over the network to this drug company sponsored message – a message that has the support of the American Urological Association but that lacks the support of other respected medical organizations such as the American Cancer Society and the US Preventive Services Task Force.

Shameful in its one-sided, imbalanced, incomplete approach, treating McEnroe’s message as gospel.

You might also like


Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Marilyn Mann

October 18, 2009 at 11:01 am

I’m wondering if under the Federal Trade Commission’s new guidelines, the Glaxo payment would have to be disclosed. See this blog post for a summary and a link to the FTC release: